Objective: To summarize the literature investigating changes in emotional expression (EE) as a function of pharmacotherapy in the treatment of ADHD and to differentiate emotional effects related to ADHD pharmacotherapy from emotional effects related to ADHD as a disorder. Method: English language articles published from January 1, 1988, through August 31, 2008 were identified through a PubMed literature search using the search terms attention, ADHD, hyperactive, hyperkinesis, and ADD cross-referenced with medication terms amphetamine, lisdexamfetamine, methylphenidate , guanfacine, atomoxetine, and clonidine. The search was limited to randomized, controlled trials. Abstracts from all identified articles were selected for further review if they met criteria including (a) presence of a placebo arm, (b) children ≤18 years of age, (c) ≥20 participants, and (b) study design elements that would allow reviewers to determine whether EE phenomena were specifically attributable to medication effects versus alternative explanations (e.g., time, maturation, baseline comorbidity, selection artifacts, or treatments other than the medication-placebo contrast). Qualifying full-text articles were reviewed for prespecified EE terms. Results: Of 148 articles that met selection criteria, 47 reported varying types of EE. Eight of these included two active treatment arms. Hence, 55 data sets were identified. Patterns of change in EE in studies meeting search criteria are discussed. Data sets that reported accounts of EE by the percentage of patients were compiled and further analyzed for specific medication classes. The changes in EE are further discussed as (a) salutary or detrimental, (b) associated with time of day or circumscribed, and (c) presumed to be caused by pharmacological effects. Conclusions: Definitive methodologies for assessing the presence of changes in EE in clinical trials and guidelines for the evaluation of EE in clinical practice are yet to be established and are needed. Such guidelines could be used by clinicians to monitor positive and negative changes in emotion when patients are taking medications for their ADHD. (J. of Att. Dis. 2011; 15(2) 101-112)
*Ahmann, P.A., Theye, F.W., Berg, R., Linquist, A.J., Van Erem, A.J., & Campbell, L.R. (2001). Placebo-controlled evaluation of amphetamine mixture-dextroamphetamine salts and amphetamine salts (Adderall): Efficacy rate and side effects. Pediatrics, 107, e10.
2.
*Ahmann, P.A., Waltonen, S.J., Olson, K.A., Theye, F.W., Van Erem, A.J., & LaPlant, R.J. ( 1993). Placebo-controlled evaluation of Ritalin side effects . Pediatrics, 91, 1101-1106.
3.
*Arnold, L.E., Lindsay, R.L., Conners, C.K., Wigal, S.B., Levine, A.J., Johnson, D.E., . . . Zeldis, J.B. ( 2004). A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology , 14, 542-554.
4.
*Barkley, R.A., McMurray, M.B., Edelbrock, C.S., & Robbins, K. ( 1990). Side effects of methylphenidate in children with attention deficit hyperactivity disorder: A systemic, placebo-controlled evaluation . Pediatrics, 86, 184-192.
5.
*Biederman, J., Boellner, S.W., Childress, A., Lopez, F.A., Krishnan, S., & Zhang, Y. ( 2007). Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: A double-blind, placebo-controlled, crossover analog classroom study. Biological Psychiatry, 62, 970-976.
6.
*Biederman, J., Heiligenstein, J.H., Faries, D.E., Galil, N., Dittmann, R., Emslie, G.J., . . . Schuh, K.J. ( 2002). Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder. Pediatrics , 110, e75.
7.
*Biederman, J., Krishnan, S., Zhang, Y., McGough, J.J., & Findling, R.L. (2007). Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/ hyperactivity disorder: A phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clinical Therapeutics, 29, 450-463.
8.
*Biederman, J., Melmed, R.D., Patel, A., McBurnett, K., Konow, J., Lyne, A., . . . Scherer, N., BAg for the SPD503 study group. (2008). A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder . Pediatrics, 121, e73-84.
9.
*Chacko, A., Pelham, W.E., Gnagy, E.M., Greiner, A., Vallano, G., Bukstein, O., & Rancurello, M. (2005). Stimulant medication effects in a summer treatment program among young children with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 44, 249-257.
10.
*Daviss, W.B., Patel, N.C., Robb, A.S., McDermott, M.P., Bukstein, O.G., Pelham, W.E., Jr., . . . Sallee, F.R. ( 2008). Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. Journal of the American Academy of Child and Adolescent Psychiatry, 47, 189-198.
11.
*Findling, R.L., Bukstein, O.G., Melmed, R.D., Lopez, F.A., Sallee, F.R., Arnold, L.E., & Pratt, R.D. ( 2008). A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder. Journal of Clinical Psychiatry, 69, 149-159.
12.
*Fine, S., & Johnston, C. ( 1993). Drug and placebo side effects in methylphenidate-placebo trial for attention deficit hyperactivity disorder. Child Psychiatry and Human Development, 24, 25-30.
13.
*Firestone, P., Musten, L.M., Pisterman, S., Mercer, J., & Bennett, S. ( 1998). Short-term side effects of stimulant medication are increased in preschool children with attention-deficit/hyperactivity disorder: A double-blind placebo-controlled study. Journal of Child and Adolescent Psychopharmacology, 8, 13-25.
14.
*Gau, S.S., Shen, H.Y., Soong, W.T., & Gau, C.S. ( 2006). An open-label, randomized, active-controlled equivalent trial of osmotic release oral system methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. Journal of Child and Adolescent Psychopharmacology , 16, 441-455.
15.
*Gillberg, C., Melander, H., von Knorring, A.L., Janols, L.O., Thernlund, G., Hagglof, B., . . . Kopp, S. ( 1997). Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. A randomized, double-blind, placebo-controlled trial. Archives of General psychiatry, 54, 857-864.
16.
*Greenhill, L.L., Findling, R.L., & Swanson, J.M. ( 2002). A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder . Pediatrics, 109, e39.
17.
*Greenhill, L.L., Muniz, R., Ball, R.R., Levine, A., Pestreich, L., & Jiang, H. ( 2006). Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/ hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 817-823.
18.
*Grizenko, N., Shayan, Y.R., Polotskaia, A., Ter-Stepanian, M., & Joober, R. ( 2008). Relation of maternal stress during pregnancy to symptom severity and response to treatment in children with ADHD. Journal of Psychiatry & Neuroscience, 33, 10-16.
19.
*Hinshaw, S.P., Buhrmester, D., & Heller, T. ( 1989). Anger control in response to verbal provocation: Effects of stimulant medication for boys with ADHD. Journal of Abnormal Child Psychology, 17, 393-407.
20.
*James, R.S., Sharp, W.S., Bastain, T.M., Lee, P.P., Walter, J.M., Czarnolewski, M., & Castellanos, F.X. (2001). Double-blind, placebo-controlled study of single-dose amphetamine formulations in ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 40, 1268-1276.
21.
*Kelsey, D.K., Sumner, C.R., Casat, C.D., Coury, D.L., Quintana, H., Saylor, K.E., . . . Allen, A.J. ( 2004). Once-daily atomoxetine treatment for children with attention-deficit/ hyperactivity disorder, including an assessment of evening and morning behavior: A double-blind, placebo-controlled trial. Pediatrics, 114, e1-8.
22.
*Klorman, R., Brumaghim, J.T., Fitzpatrick, P.A., Borgstedt, A.D., & Strauss, J. ( 1994). Clinical and cognitive effects of methylphenidate on children with attention deficit disorder as a function of aggression/oppositionality and age. Journal of Abnormal Psychology, 103, 206-221.
23.
*Kratochvil, C.J., Faries, D., Vaughan, B., Perwien, A., Busner, J., Saylor, K., . . . Swindle, R. ( 2007). Emotional expression during attention-deficit/hyperactivity disorders treatment: Initial assessment of treatment effects. Journal of Child and Adolescent Psychopharmacology, 17, 51-62.
24.
*Manos, M.J., Short, E.J., & Findling, R.L. (1999). Differential effectiveness of methylphenidate and Adderall in school-age youths with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 813-819.
25.
*Matza, L.S., Rentz, A.M., Secnik, K., Swensen, A.R., Revicki, D.A., Michelson, D., . . . Kratochvil, C.J. (2004). The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder. Journal of Developmental and Behavioral Pediatrics, 25, 166-174.
26.
*Mayes, S.D., Crites, D.L., Bixler, E.O., Humphrey, F.J., 2nd , & Mattison, R.E. (1994). Methylphenidate and ADHD: Influence of age, IQ and neurodevelopmental status. Developmental Medicine and Child Neurology, 36, 1099-1107.
27.
*McCracken, J.T., Biederman, J., Greenhill, L.L., Swanson, J.M., McGough, J.J., Spencer, T.J., . . . Tulloch, S. ( 2003). Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 42, 673-683.
28.
*McGough, J.J., Biederman, J., Wigal, S.B., Lopez, F.A., McCracken, J.T., Spencer, T., . . . Tulloch, S.J. ( 2005). Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 44, 530-538.
29.
*Michelson, D., Allen, A.J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., . . . Harder, D. ( 2002). Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study. American Journal of Psychiatry, 159, 1896-1901.
30.
*Newcorn, J.H., Kratochvil, C.J., Allen, A.J., Casat, C.D., Ruff, D.D., Moore, R.J., & Michelson, D.; Atomoxetine/ Methylphenidate Comparative Study Group. ( 2008). Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: Acute comparison and differential response. American Journal of Psychiatry , 165, 721-730.
31.
*Newcorn, J.H., Spencer, T.J., Biederman, J., Milton, D.R., & Michelson, D. ( 2005). Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 44, 240-248.
32.
*Pelham, W.E., Aronoff, H.R., Midlam, J.K., Shapiro, C.J., Gnagy, E.M., Chronis, A.M., . . . Waxmonsky, J. ( 1999). A comparison of Ritalin and Adderall: Efficacy and time-course in children with attention-deficit/hyperactivity disorder. Pediatrics, 103, e43.
33.
*Pelham, W.E., Burrows-Maclean, L., Gnagy, E.M., Fabiano, G.A., Coles, E.K., Tresco, K.E., . . . Hoffman, M.T. ( 2005). Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD. Experimental and Clinical Psychopharmacology, 13, 111-126.
34.
*Pelham, W.E., Gnagy, E.M., Chronis, A.M., Burrows-MacLean, L., Fabiano, G.A., Onyango, A.N., . . . Steiner, R.L. ( 1999). A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics, 104, 1300-1311.
35.
*Pelham, W.E., Jr, Greenslade, K.E., Vodde-Hamilton, M., Murphy, D.A., Greenstein, J.J., Gnagy, E.M., . . . Dahl, R.E. ( 1990). Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: A comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics, 86, 226-237.
36.
*Pelham, W.E., Jr., Manos, M.J., Ezzell, C.E., Tresco, K.E., Gnagy, E.M., Hoffman, M.T., . . . Morse, G. ( 2005). A dose-ranging study of a methylphenidate transdermal system in children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 44, 522-529.
37.
Perwien, A.R., Kratochvil, C.J., Faries, D., Vaughan, B., Busner, J.Saylor, K.E., . . . Swindle, R. ( 2008). Emotional expression in children treated with ADHD medication: Development of a new measure. Journal of Attention Disorders , 11, 568-579.
38.
*Pliszka, S.R., Browne, R.G., Olvera, R.L., & Wynne, S.K. ( 2000). A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder . Journal of the American Academy of Child and Adolescent Psychiatry, 39, 619-626.
39.
*Rapport, M.D., Randall, R., & Moffitt, C. ( 2002). Attention-deficit/ hyperactivity disorder and methylphenidate: A dose-response analysis and parent-child comparison of somatic complaints . Journal of Attention Disorders, 6, 15-24.
40.
*Schachar, R.J., Tannock, R., Cunningham, C., & Corkum, P.V. ( 1997). Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 754-763.
41.
*Short, E.J., Manos, M.J., Findling, R.L., & Schubel, E.A. ( 2004). A prospective study of stimulant response in preschool children: Insights from ROC analyses. Journal of the American Academy of Child and Adolescent Psychiatry, 43, 251-259.
42.
*Silva, R.R., Muniz, R., Pestreich, L., Childress, A., Brams, M., Lopez, F.A., & Wang, J. ( 2006). Efficacy and duration of effect of extended-release dexmethylphenidate versus placebo in schoolchildren with attention-deficit/hyperactivity disorder . Journal of Child and Adolescent psychopharmacology, 16, 239-251.
43.
*Smithee, J.A., Klorman, R., Brumaghim, J.T., & Borgstedt, A.D. (1998). Methylphenidate does not modify the impact of response frequency or stimulus sequence on performance and event-related potentials of children with attention deficit hyperactivity disorder. Journal of Abnormal Child Psychology, 26, 233-245.
44.
*Spencer, T.J., Wilens, T.E., Biederman, J., Weisler, R.H., Read, S.C., & Pratt, R. ( 2006). Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: A 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Clinical Therapeutics, 28, 266-279.
45.
*Swanson, J.M., Wigal, S.B., Wigal, T., Sonuga-Barke, E., Greenhill, L.L., Biederman, J., . . . Hatch, S.J. ( 2004). A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics, 113, e206-216.
46.
*Whalen, C.K., Henker, B., Buhrmester, D., Hinshaw, S.P., Huber, A., & Laski, K. ( 1989). Does stimulant medication improve the peer status of hyperactive children? Journal of Consulting and Clinical Psychology , 57, 545-549.
47.
*Wigal, S., Swanson, J.M., Feifel, D., Sangal, R.B., Elia, J., Casat, C.D., . . . Conners, C.K. ( 2004). A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 43, 1406-1414.
48.
*Wigal, T., Greenhill, L., Chuang, S., McGough, J., Vitiello, B., Skrobala, A., . . . Stehli, A. ( 2006). Safety and tolerability of methylphenidate in preschool children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 1294-1303.
